All Oncology News

FDA Grants Fast Track Status to Nemvaleukin Alfa for Mucosal Melanoma

August 2nd 2021

The FDA has granted a fast track designation to nemvaleukin alfa as a potential therapeutic option for patients with mucosal melanoma.

Imetelstat Elicits Efficacy Across Molecularly Defined Subgroups of Lower-Risk MDS

August 2nd 2021

Treatment with imetelstat demonstrated clinical efficacy across molecularly defined subgroups of patients with heavily transfused, lower-risk myelodysplastic syndrome who did not harbor 5q deletions and were relapsed/refractory to erythropoiesis-stimulating agents.

Soliman Details Ongoing Novel Immunotherapeutic Research Efforts at Moffitt, Recent Developments in Breast Cancer

August 2nd 2021

Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML

August 2nd 2021

The combination of ivosidenib plus azacitidine significantly improved event-free survival compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE trial.

Sotorasib Flips the Switch for Patients With KRAS G12C-Mutant NSCLC

August 2nd 2021

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

August 1st 2021

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

KRAS Inhibitors Reach New Milestones in NSCLC

July 31st 2021

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

Dr. Arcila on Choosing Between Molecular Tests in Lung Cancer

July 31st 2021

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

July 31st 2021

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

July 31st 2021

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

July 30th 2021

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

July 30th 2021

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

July 30th 2021

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia

July 30th 2021

The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Zanubrutinib Significantly Prolongs PFS Over Chemoimmunotherapy in Treatment-Naïve CLL

July 30th 2021

Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.

Adjuvant Nivolumab Approved in Europe for Select Esophageal or GEJ Cancers

July 30th 2021

The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

July 29th 2021

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up

July 29th 2021

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

FDA Warns of Increased Risk of Death With Melphalan Flufenamide in Multiple Myeloma

July 29th 2021

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma, has indicated that the doublet resulted in an increased risk of death in this population.

Lakshmanan Krishnamurti Named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Smilow Cancer Hospital

July 29th 2021

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

Chordomas: Rare, Indolent and Linked With Poor Outcomes, But Research Efforts Continue

July 29th 2021

Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull.

Enasidenib Elicits Clinical Efficacy in High-Risk, IDH2-Mutated MDS

July 29th 2021

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.